Skip to content

Biomarkers for vascular cognitive impairment: a prospective study

Biomarkers for vascular cognitive impairment: a prospective study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063112
Enrollment
Unknown
Registered
2022-08-31
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vascular cognitive impairment (VCI)

Interventions

case series:None

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years; 2. Meet any of the following conditions: (1) Patients with small cerebral vascular disease: 1) Age range: 50-80 years old; 2) Diagnostic criteria for CSVD: moderate to severe leukoencephalopathy (Fazekas deep >1 score or paraventricular >2 score); Or mild leukoencephalopathy (Fazekas deep =1 point or paraventricular =2 points) with lacunae or microbleeding; (2) Patients with acute ischemic stroke: 1) Duration of onset <=14 days; 2) According to the 2013 American AHA/ASA New Definition of Stroke, clinically diagnosed cases of acute ischemic stroke are defined as follows: acute onset; Focal brain/spinal/retinal nerve dysfunction; Symptoms and signs persist for more than 24 hours; Exclude non-vascular lesions; Pathological or imaging evidence excluded cerebral hemorrhage and other lesions, confirming the responsible ischemic focus; 3. Able to complete questionnaire survey, physical examination, head MRI and other medical examinations; 4. Voluntarily participate in this survey and subsequent investigations, provide biological samples, and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Meet any of the following conditions: (1) Patients with small cerebral vascular disease: stroke events in the past 6 months; (2) Patients with acute ischemic stroke: receiving intravenous thrombolysis, intra-arterial thrombectomy and bridging therapy within the time window of the acute phase; Or diagnosed with dementia before stroke; 2. Patients with pregnancy, malignant tumor, vital organ failure or life expectancy less than 3 years; 3. Patients with congenital mental impairment or other serious neurological or mental diseases; 4. Severe vision or hearing impairment may not cooperate with neuropsychological evaluators; 5. There are contraindications for MRI examination (such as metal implant, claustrophobia, etc.).

Design outcomes

Primary

MeasureTime frame
Cognition;Mental behavior;Imaging changes;

Countries

China

Contacts

Public ContactXu Jun
neurojun@126.com+86 13581569328

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026